References in periodicals archive ?
24, 2015, is based on data from three Phase 3 studies, including two pooled placebo-controlled trials in more than 1,000 patients and a head-to-head study evaluating etelcalcetide compared with cinacalcet.
First-line conservative measures include aggressive wound care, systemic antibiotics, non-calcium containing phosphate binders, cinacalcet (a calcium-receptor stimulating agent), bisphosphonates and, the most promising of all, sodium thiosulfate.
In many patients with moderate to severe sHPT, cinacalcet, an oral-only calcimimetic agent, is also required, and for some, surgical therapy (typically subtotal parathyroidectomy [PTX]) may be necessary (National Kidney Foundation 2003).
4% conocia que los quelantes sirven para controlar el fosforo; el 50,9% de la poblacion estudiada piensa que la toma de estos farmacos son importantes para el control del fosforo; un 28,3% desconoce su importancia y el 13,2% "porque lo dice el medico" (tabla 3) y el 9,4% de la poblacion que tomaba cinacalcet (35% de los encuestados) sabia que este farmaco disminuye la secrecion de PTH.
Washington, November 5 ( ANI ): Cinacalcet - a drug commonly prescribed to patients with kidney failure and a disturbance of bone and mineral metabolism known as secondary hyperparathyroidism - does not significantly reduce the risk of death or major cardiovascular events, a study led by an international team of researchers has found.
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and healthrelated quality of life in secondary hyperparathyroidism.
The company expects the following clinical data in 2012: Sensipar/Mimpara Phase 3 Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) study Talimogene laherparepvec Phase 3 melanoma study - interim data for the primary endpoint (durable response) AMG 785 - Phase 2 fracture ealing studies AMG 145 - Phase 2 studies
Cinacalcet has also been used in conjunction with calcitonin and has demonstrated a highly effective reduction in PTH levels (15).
The management of hyperparathyroidism consists of managing hyperphosphatemia, hypocalcemia and the use of specific PTH-lowering agents such as calcitriol, or vitamin D analogues, and cinacalcet.
Cinacalcet, the only drug in its class currently available, treats the secondary hyperparathyroidism of renal disease by lowering phosphate.
Cinacalcet, a drug that has been linked to reducing bone loss in patients with kidney disease, is in its third phase of clinical trials.
Biovitrum will also have co-promotion rights in the Nordic region for all products developed under the agreement as well as for Amgen's cinacalcet hydrochloride, a treatment for some hyperparathyroid conditions, and palifermin, a therapy for treating chemotherapy-related inflammations of the mouth.